Deliver Your News to the World

CybeRelease: (OTC: TEDG) Signs Letter of Intent to Acquire China’s Largest Vaccine Distributor


(CybeRelease, June 21, 2006) - Lake Harmony, PA - Techedge Inc. (OTCBB: TEDG) announced that China BioPharma’s subsidiary Zhejiang Tianyuan Biotech Co., has signed a letter of intent to acquire Hainan CITIC Biopharmaceutical Development Co. (“Hainan CITIC”).

Under the agreement Zhejiang Tianyuan Biotech Co. would acquire over 90% interest in Hainan CITIC Biopharmaceutical Development Co., with the remaining interest being owned by China CDC (China’s Center for Disease Control).

Hainan CITIC is the largest vaccine distributor in China, with an extensive customer network in most major cities within the country. The company has established its ’cold chain’ for distribution logistics for most major parts of China. The Company was the distributor for major international vaccine suppliers, such as GSK and Chiron Vaccines.

“We are very excited about this acquisition,” Dr. Jean-Denis Shu, CEO of China Biopharma Limited stated, “this acquisition will bring us an effective platform and strong market position for promoting our vaccines and other related biopharmaceutical products in China.”

For a Free Newsletter and more information, go to

To read the complete release, go to .

CybeRelease Gainers are Ceradyne, Inc. (Nasdaq: CRDN), Expeditors International of Washington, Inc. (Nasdaq: EXPD), Hibbett Sporting Goods, Inc. (Nasdaq: HIBB), Alvarion Ltd. (Nasdaq: ALVR), Progenics Pharmaceuticals Inc. (Nasdaq: PGNX), CFC International, Inc. (Nasdaq: CFCI), Broadwing Corporation (Nasdaq: BWNG) and FSI International, Inc. (Nasdaq: FSII).

CybeRelease Decliners areGolf Galaxy, Inc. (Nasdaq: GGXY), Linktone Ltd. (Nasdaq: LTON), Herley Industries, Inc. (Nasdaq: HRLY), ECI Telecom Ltd. (Nasdaq: ECIL), Ionatron, Inc. (Nasdaq: IOTN), Orchid Cellmark Inc. (Nasdaq: ORCH), NTELOS Holdings Corp. (Nasdaq: NTLS) and EXACT Sciences Corporation (Nasdaq: EXAS).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid CybeRelease $500.00 for the publication of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation and do no trading of any kind.


This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.